Moreover, the authors studied publically available datasets (cBioPortal) and reported that PP2A activation status could be deregulated in more than 50% of basal breast cancer tumors due to alterations affecting PP2A subunits or deregulation of endogenous PP2A inhibitors such as SETBP1, SET or CIP2A [26]. This evidence concerns the gene SET and breast cancer.